Beaulieu P L, Wernic D, Abraham A, Anderson P C, Bogri T, Bousquet Y, Croteau G, Guse I, Lamarre D, Liard F, Paris W, Thibeault D, Pav S, Tong L
Bio-Méga Research Division, Boehringer Ingelheim (Canada) Ltd., Laval (Québec), Canada.
J Med Chem. 1997 Jul 4;40(14):2164-76. doi: 10.1021/jm9606608.
A series of HIV protease inhibitors containing a novel (hydroxyethyl)amidosuccinoyl core has been synthesized. These peptidomimetic structures inhibit viral protease activity at low nanomolar concentrations (IC50 < 10 nM for HIV-1 protease). The inhibition constant (Ki) for inhibitor 19 was determined to be 7.5 pM against HIV-1 and 1.2 nM against HIV-2 proteases, respectively. Several compounds (19-24) inhibited HIV-1 replication in cell culture assays with 50% effective concentrations (EC50) = 3.7-35 nM. This series of inhibitors was found to exhibit poor bioavailability (< 10%) in the rat, following oral administration. The synthesis and biological properties of these compounds are discussed. In addition, an X-ray structure of one of these inhibitors (23) in complex with HIV-2 protease provides insight into the binding mode of this novel class of HIV protease inhibitors.
已合成了一系列含有新型(羟乙基)氨基琥珀酰核心的HIV蛋白酶抑制剂。这些拟肽结构在低纳摩尔浓度下抑制病毒蛋白酶活性(HIV-1蛋白酶的IC50 < 10 nM)。抑制剂19对HIV-1蛋白酶的抑制常数(Ki)测定为7.5 pM,对HIV-2蛋白酶的抑制常数为1.2 nM。几种化合物(19 - 24)在细胞培养试验中抑制HIV-1复制,50%有效浓度(EC50) = 3.7 - 35 nM。经口服给药后,发现该系列抑制剂在大鼠体内的生物利用度较差(< 10%)。讨论了这些化合物的合成及生物学特性。此外,其中一种抑制剂(23)与HIV-2蛋白酶复合物的X射线结构为这类新型HIV蛋白酶抑制剂的结合模式提供了深入了解。